The Federal Trade Commission has brought yet another merger challenge without any evidence of competitive harm. Still, despite its weaknesses, the FTC’s complaint against Amgen and Horizon provides insights into the agency’s thinking and may hold clues regarding anticipated new merger guidelines.
